title: [Combined radiotherapy and Zelboraf® is associated with risk of severe radiotherapy-induced lesions].
authors.affiliation: Département de dermatologie et allergologie, bâtiment des spécialités médicales, 6, rue du Morvan, 54500 Vandœuvre-lès-Nancy, France. Electronic address: jl.schmutz@chu-nancy.fr.
authors.forename: J-L
authors.initials: JL
authors.lastname: Schmutz
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D059248:Chemoradiotherapy / Q000009:adverse effects*; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D011836:Radiation Tolerance / Q000187:drug effects*; D011855:Radiodermatitis / Q000139:chemically induced*; D013449:Sulfonamides / Q000009:adverse effects*; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib